GSK (NYSE:GSK) Shares Gap Up – What’s Next?

GSK PLC Sponsored ADR (NYSE:GSK) shares gapped up before the market opened on Monday . The stock had previously closed at $48.13, but opened at $50.29. GSK shares last traded at $49.73, with a volume of 744,536 shares changing hands.

More GSK News

Here are the key news stories impacting GSK this week:

• Positive Sentiment: Berenberg upgraded GSK from “hold” to “buy,” citing an improved growth outlook. The endorsement may support sentiment by highlighting potential value in GSK’s pipeline and earnings prospects. GSK upgraded at Berenberg on growth outlook
• Positive Sentiment: GSK agreed to acquire global rights to an experimental trispecific T-cell engager from Chimagen Biosciences for up to $750 million. The multiple myeloma therapy expands GSK’s oncology portfolio and could add a differentiated asset, although its value depends on clinical and regulatory success. GSK strikes up to $750 million deal for cancer-targeting drug
• Positive Sentiment: Encouraging lung-cancer data strengthened GSK’s oncology investment case. Jideytro showed high response rates and durable disease control in first-line ROS1-positive non-small-cell lung cancer, supporting plans for an expanded U.S. filing. Separately, GSK reported positive Phase III survival data for its antibody-drug conjugate in relapsed small-cell lung cancer. These results could broaden the commercial opportunity for the company’s oncology pipeline. GSK Presents Jideytro Data for Potential Use in First-Line NSCLC
• Neutral Sentiment: At the Morgan Stanley Global Healthcare Conference, GSK discussed its business and pipeline strategy. The presentation may provide additional context for investors, but no specific new financial guidance was identified in the available report. GSK Presents at Morgan Stanley Healthcare Conference
• Negative Sentiment: GSK plans to close its Dresden, Germany, vaccine manufacturing site by summer 2027, putting 641 jobs at risk. The move reflects weaker demand for traditional egg-based flu vaccines and excess manufacturing capacity. While the restructuring could improve long-term efficiency, it highlights pressure in the vaccine business and may create near-term costs. GSK Cuts 641 Jobs in Vaccine Manufacturing Restructuring

Analyst Ratings Changes

Several research analysts have commented on GSK shares. Jefferies Financial Group raised shares of GSK to a “strong-buy” rating in a report on Friday, July 17th. Citigroup started coverage on shares of GSK in a report on Friday, July 24th. They issued a “neutral” rating on the stock. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of GSK in a research report on Thursday, July 30th. HSBC reissued a “hold” rating on shares of GSK in a research note on Thursday, September 10th. Finally, Weiss Ratings lowered GSK from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Wednesday, July 29th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, seven have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $56.50.

GSK Trading Down 0.1%

The firm has a market capitalization of $101.15 billion, a P/E ratio of 15.64, a price-to-earnings-growth ratio of 2.10 and a beta of 0.35. The company has a quick ratio of 0.52, a current ratio of 0.82 and a debt-to-equity ratio of 0.81. The firm’s 50-day simple moving average is $51.16 and its 200-day simple moving average is $52.62.

GSK (NYSE:GSK) last released its quarterly earnings results on Tuesday, July 28th. The pharmaceutical company reported $1.36 EPS for the quarter, topping analysts’ consensus estimates of $1.27 by $0.09. The business had revenue of $11.14 billion during the quarter, compared to analysts’ expectations of $11.02 billion. GSK had a net margin of 14.56% and a return on equity of 43.23%. The business’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.47 EPS. GSK has set its FY 2026 guidance at 4.900-5.000 EPS. Analysts anticipate that GSK PLC Sponsored ADR will post 4.81 EPS for the current year.

GSK Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, October 8th. Investors of record on Friday, August 14th will be given a $0.4515 dividend. This represents a $1.81 annualized dividend and a yield of 3.6%. This is a boost from GSK’s previous quarterly dividend of $0.44. The ex-dividend date is Friday, August 14th. GSK’s dividend payout ratio (DPR) is presently 55.63%.

Institutional Investors Weigh In On GSK

Large investors have recently added to or reduced their stakes in the company. Fisher Asset Management LLC grew its position in shares of GSK by 3.0% during the 4th quarter. Fisher Asset Management LLC now owns 33,195,985 shares of the pharmaceutical company’s stock valued at $1,627,931,000 after acquiring an additional 968,370 shares during the period. NewEdge Advisors LLC raised its holdings in GSK by 842.9% in the 2nd quarter. NewEdge Advisors LLC now owns 953,574 shares of the pharmaceutical company’s stock worth $49,986,000 after purchasing an additional 852,437 shares during the period. BI Asset Management Fondsmaeglerselskab A S lifted its position in GSK by 2,032.8% during the fourth quarter. BI Asset Management Fondsmaeglerselskab A S now owns 854,331 shares of the pharmaceutical company’s stock valued at $41,896,000 after purchasing an additional 814,275 shares in the last quarter. Waverly Advisors LLC lifted its position in GSK by 1,372.8% during the second quarter. Waverly Advisors LLC now owns 290,593 shares of the pharmaceutical company’s stock valued at $15,233,000 after purchasing an additional 270,863 shares in the last quarter. Finally, Keystone Financial Planning Inc. grew its holdings in GSK by 3,114.8% during the second quarter. Keystone Financial Planning Inc. now owns 195,590 shares of the pharmaceutical company’s stock valued at $10,253,000 after purchasing an additional 189,506 shares during the period. Hedge funds and other institutional investors own 15.74% of the company’s stock.

GSK Company Profile

GSK plc is a global biopharmaceutical company headquartered in Brentford, England. The company researches, develops and manufactures medicines and vaccines for the prevention and treatment of disease, serving patients and healthcare providers in markets around the world.

GSK focuses on specialty medicines and vaccines in areas including infectious diseases, HIV, respiratory disease, immunology and oncology. Its products include prescription medicines, long-acting treatments and vaccines designed to protect against diseases such as shingles, meningitis, influenza and respiratory syncytial virus (RSV).

The company was formed in 2000 through the merger of Glaxo Wellcome and SmithKline Beecham.